Patents Examined by Alexandra F Connors
-
Patent number: 11920159Abstract: A method for revitalizing mesenchymal stem cells (MSC) maintained in culture by transducing the MSC with vectors encoding a specific gene combination, as well as methods of use of MSC so revitalized in co-culturing hematopoietic stem cells.Type: GrantFiled: June 7, 2018Date of Patent: March 5, 2024Assignee: ALBERT EINSTEIN COLLEGE OF MEDICINEInventors: Paul S. Frenette, Fumio Nakahara
-
Patent number: 11802272Abstract: Methods of, treatments using, and devices for restoring the regenerative capability for mesenchymal stem cells and isolating and expanding a small subpopulation of less defective mesenchymal stem cells from the bone marrow stromal cells of people with decreased quality and/or quantity of mesenchymal stem cells, such as elderly people.Type: GrantFiled: November 4, 2016Date of Patent: October 31, 2023Assignee: The Board of Regents of The University of Texas SystemInventors: Travis Block, Milos Marinkovic, Xiao-dong Chen
-
Patent number: 11773387Abstract: The present invention relates to a device and a method for inducing pluripotent cells using energy and, more specifically, has an effect of inducing new type pluripotent cells having pluripotent characteristics by applying energy such as ultrasonic waves, lasers or heat treatment to differentiated cells.Type: GrantFiled: December 4, 2015Date of Patent: October 3, 2023Assignee: STEMON Inc.Inventor: Soonhag Kim
-
Patent number: 11752175Abstract: This invention relates to methods and compositions for detecting, identifying and treating glaucoma diseases. More particularly, this invention discloses compositions and methods for affecting intraocular pressure and increasing ocular outflows in glaucoma. Compositions and methods provided include purified and synthesized extracellular vesicle complexes from glaucoma ocular humor for use in methods and devices for detecting, characterizing and treating glaucoma diseases along with active agents. The presence of extracellular vesicle complexes in glaucoma can also be used as a biomarker.Type: GrantFiled: September 21, 2019Date of Patent: September 12, 2023Assignee: Cornell UniversityInventors: John T. G. Pena, James Murray Mitchell, Harmon Lawrence Remmel
-
Patent number: 11746329Abstract: This disclosure pertains to a non-living biological product. Particularly, exosomes derived from stem cells can help restore heart function. According to certain embodiments, a fluid-induced shear stress mechanical stimulation process of stem cells is used to augmented quantity and quality of exosomes produced from stem cells. These exosomes serve as a therapeutic agent for the regenerative repair of diseases, such as diseased heart tissues. Therefore, compositions comprising the exosomes derived from stem cells and methods of treating a degenerative disease by administering the exosomes isolated from stem cells are also provided.Type: GrantFiled: December 11, 2020Date of Patent: September 5, 2023Assignee: THE FLORIDA INTERNATIONAL UNIVERSITY BOARD OF TRUSTEESInventors: Sharan Ramaswamy, Manuel Perez, Yih-Mei Lin
-
Patent number: 11672756Abstract: The present invention provides a temperature sensitive hydrogel composition including a nucleic acid and chitosan. Since the hydrogel has excellent biocompatibility and biostability, and simultaneously has sol-gel phase transition properties depending on temperature changes, the hydrogel is present in a sol state at room temperature and becomes a gel when the hydrogel is injected into the human body or applied on the surface of epithelial skin and the temperature increases. Thus, the temperature-sensitive hydrogel of the present invention can be directly injected into and applied on certain parts requiring treatment and the retention and attaching time of a drug is increased through gelation depending on the temperature so that drug efficacy is sufficiently exhibited. Therefore, it is expected that the temperature-sensitive hydrogel of the present invention can be utilized for various treatments.Type: GrantFiled: February 29, 2016Date of Patent: June 13, 2023Assignee: PHARMARESEARCH CO., LTD.Inventors: Ik Soo Kim, Han Gyu Kim, Cheol Am Hong, Su Yeon Lee
-
Patent number: 11591573Abstract: The invention provides methods of preparing a sample of viable diseased cells obtained from a human subject for clinical testing, wherein the methods inhibit anoikis and/or anoikis in the cells while maintaining the physiological functions and genomic composition of the cells when they were in vivo. In the methods of the invention, primary cells are cultured in media comprising at least one anoikis inhibitor, preferably at least one inhibitor of an intrinsic anoikis pathway and at least one inhibitor of an extrinsic anoikis pathway, under anti-anoikis atmospheric conditions, such as greater than 2% and less than 20% oxygen. Method combining multiple culturing conditions, including surface attachment under conditions that inhibit anoikis, are also provided. Compositions and kits for use in the methods of the invention are also provided.Type: GrantFiled: April 11, 2018Date of Patent: February 28, 2023Assignee: Celcuity Inc.Inventors: Lance Gavin Laing, Ben Rich, Abhijit Dandapat
-
Patent number: 11485953Abstract: The present disclosure provides for a cell stabilizing medium which comprises gelatin. The cell stabilizing medium help maintain cell viability, e.g., after thawing of a biological material post-cryopreservation.Type: GrantFiled: October 3, 2017Date of Patent: November 1, 2022Assignee: TRANSWELL BIOTECH CO., LTD.Inventors: Ya-Hsuan Chang, Cheng-Yi Lin, Chih-Yuan Chao
-
Patent number: 11413311Abstract: Methods of treating multiple sclerosis are provided, comprising parenterally administering glatiramer acetate in a sustained-release depot form, and administering adipose-derived stem cells into the central nervous system. According to some aspects the combined treatments provide synergistic effects. In particular the combined therapies offer benefits to progressive forms of multiple sclerosis.Type: GrantFiled: May 15, 2017Date of Patent: August 16, 2022Assignees: MAPI PHARMA LTD., STEM CELL MEDICINE LTD.Inventors: Ehud Marom, Nadav Bleich Kimelman, Frida Grynspan
-
Patent number: 11401510Abstract: Described herein is a method of generating in-vitro differentiated airway basal cells and compositions thereof. Also described herein is a method of treating a pulmonary disease comprising administering the in-vitro differentiated airway basal cells and compositions thereof. In another aspect, described herein is a disease model comprising patient-derived or genetically modified in-vitro differentiated airway basal cells and compositions thereof.Type: GrantFiled: February 19, 2021Date of Patent: August 2, 2022Assignees: TRUSTEES OF BOSTON UNIVERSITY, THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEMInventors: Finn Joseph Hawkins, Darrell N. Kotton, Shingo Suzuki, Brian R. Davis, Cristina Barillà
-
Patent number: 11395863Abstract: A method is disclosed for modifying a sheet-shaped cell culture containing at least two types of cells. The method includes soaking the sheet-shaped cell culture in a low nutrient isotonic solution; and changing a content ratio of the at least two cell types constituting the sheet-shaped cell culture.Type: GrantFiled: November 13, 2018Date of Patent: July 26, 2022Assignee: TERUMO KABUSHIKI KAISHAInventors: Kenji Oyama, Ryohei Takeuchi, Toshikazu Takeuchi
-
Patent number: 11371020Abstract: This disclosure relates to methods of generating pacemaker cells for use in therapeutic strategies that address a heart that beats abnormally. In certain embodiments, one mixes cells with an epithelial-to-mesenchymal transformation inhibitor in combination with a nucleic acid encoding a transcription factor such as a vector that encodes a transcription factor such as Tbx18 in operable combination with a eukaryotic promoter to produce pacemaker cells that are then transplanted into the heart.Type: GrantFiled: May 2, 2017Date of Patent: June 28, 2022Assignees: Emory University, Children's Healthcare of Atlanta, Inc.Inventor: Hee Cheol Cho
-
Patent number: 11359178Abstract: The present invention provides a method for producing parasympathetic neurons from neural crest cells or autonomic neural progenitor cells derived therefrom, comprising a step of culturing the neural crest cells or autonomic neural progenitor cells derived therefrom in the presence of a cAMP production promoter, a BDNF signaling pathway activator, a GDNF signaling pathway activator, an NGF signaling pathway activator, an NT-3 signaling pathway activator, vitamin C, a protein kinase C activator, and a retinoic acid receptor agonist.Type: GrantFiled: August 23, 2019Date of Patent: June 14, 2022Assignee: NATIONAL INSTITUTE OF ADVANCED INDUSTRIAL SCIENCE AND TECHNOLOGYInventors: Yuzo Takayama, Yasuyuki Kida
-
Patent number: 11293870Abstract: A vital stain for observation under multiphoton laser microscopy, the vital stain comprising one or more edible dye compounds.Type: GrantFiled: March 28, 2014Date of Patent: April 5, 2022Assignee: MIE UNIVERSITYInventors: Akira Mizoguchi, Takeshi Fujiwara, Koji Tanaka, Shujie Wang, Kousyoku Sai, Kazushi Kimura
-
Patent number: 11241516Abstract: The present invention refers to a process for preparing a biomaterial scaffold said method comprising, (a) providing a hydrogel comprising a fibrin network and a polysaccharide network; (b) subjecting the hydrogel of step a) to a freeze-thawing process to physically crosslink the hydrogel; and (c) subjecting the physically cross-linked hydrogel obtained after conducting the step b), to a lyophilization. The invention also relates to the biomaterial scaffold obtainable by the process as defined above, as well said biomaterial scaffold for its use to partially or completely increase, restore or replace the functional activity of a diseased or damaged oral mucosa.Type: GrantFiled: October 23, 2015Date of Patent: February 8, 2022Assignee: HISTOCELL, S.L.Inventors: María Begoña Castro Feo, Amparo Baiget Orts